Sangamo Therapeutics, Inc. reports impairment charges for the three months ended September 30, 2023. For the quarter, Impairment of long-lived assets was $44.8 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.546 USD | +4.32% | -0.13% | +2.17% |
05-09 | Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000 | MT |
03-22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.17% | 109M | |
+3.32% | 108B | |
+10.92% | 104B | |
+1.28% | 22.33B | |
-11.97% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.99% | 17.64B | |
+4.90% | 14.05B | |
+34.49% | 12.51B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023